The WHO Model List of Essential Medicines (a.k.a. Essential Medicines List or EML), published by the World Health Organization (WHO), contains the medications considered to be most effective and safe to meet the most important needs in a health system. The list is frequently used by countries to help develop their own local lists of essential medicines. , more than 155 countries have created national lists of essential medicines based on the World Health Organization's model list. This includes both developed and developing countries.
The list is divided into core items and complementary items. The core items are deemed to be the most cost-effective options for key health problems and are usable with little additional health care resources. The complementary items either require additional infrastructure such as specially trained health care providers or diagnostic equipment or have a lower costâÂÂbenefit ratio. About 25% of items are in the complementary list. Some medications are listed as both core and complementary. While most medications on the list are available as generic products, being under patent does not prevent inclusion.
The first list was published in 1977 and included 208 medications. The WHO updates the list every two years. There are 306 medications in the 14th list in 2005, 410 in the 19th list in 2015, 433 in the 20th list in 2017, 460 in the 21st list in 2019, and 479 in the 22nd list in 2021. Various national lists contain between 334 and 580 medications. The Essential Medicines List (EML) was updated in September 2025 to its 24th edition. The list contains recommendations for 523 medications.
A separate list for children up to twelve years of age, known as the WHO Model List of Essential Medicines for Children (EMLc), was created in 2007, and is in its 10th edition. It was created to make sure that the needs of children were systematically considered such as availability of proper formulations. Everything in the children's list is also included in the main list. The list and notes are based on the 19th to 24th edition of the main list. Therapeutic alternatives with similar clinical performance are listed for some medicines and they may be considered for national essential medicines lists. The 10th Essential Medicines List for Children was updated in September 2025.
Note: An ñ indicates a medicine is on the complementary list.
Anaesthetics, preoperative medicines and medical gases
General anaesthetics and oxygen
Inhalational medicines
Injectable medicines
Local anaesthetics
Complementary:
Preoperative medication and sedation for short-term procedures
Medical gases
Medicines for pain and palliative care
Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
Opioid analgesics
Complementary:
Medicines for other common symptoms in palliative care
Antiallergics and medicines used in anaphylaxis
Antidotes and other substances used in poisonings
Non-specific
Specific
Complementary:
Medicines for neurological disorders
Medicines for central nervous system disorders
Antiseizure medicines
Complementary:
Medicines for multiple sclerosis
Complementary:
Medicines for parkinsonism
Medicines for cerebral palsy
Medicines for headache disorders
Medicines for acute migraine attacks
Medicines for migraine prophylaxis
Medicines for cluster headache
Medicines for central nervous system infections
Medicines for bacterial central nervous system infections
Complementary:
Medicines for viral central nervous system infections
Medicines for peripheral nervous system disorders
Medicines for Guillain-Barré syndrome
Complementary:
Medicines for myasthenia gravis
Complementary:
Anti-infective medicines
Anthelminthics
Intestinal anthelminthics
Antifilarials
Antischistosomals and other antinematode medicines
Complementary:
Cysticidal medicines
Complementary:
Antibacterials
Access group antibiotics
This group includes antibiotics that have activity against a wide range of commonly encountered susceptible pathogens while also showing lower resistance potential than antibiotics in the other groups.
Watch group antibiotics
This group includes antibiotic classes that have higher resistance potential and includes most of the highest priority agents among the Critically Important Antimicrobials for Human Medicine and/or antibiotics that are at relatively high risk of selection of bacterial resistance.
Complementary:
Reserve group antibiotics
This group includes antibiotics and antibiotic classes that should be reserved for treatment of confirmed or suspected infections due to multi-drug-resistant organisms. Complementary:
Antileprosy medicines
Antituberculosis medicines
Antifungal medicines
Complementary:
Antiviral medicines
Antiherpes medicines
Antiretrovirals
Nucleoside/nucleotide reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors
Protease inhibitors
Integrase inhibitors
Fixed-dose combinations of antiretroviral medicines
Medicines for prevention of HIV-related opportunistic infections
Other antivirals
Complementary:
Antihepatitis medicines
Medicines for hepatitis B
Nucleoside/Nucleotide reverse transcriptase inhibitors
Medicines for hepatitis C
Pangenotypic direct-acting antiviral combinations
Non-pangenotypic direct-acting antiviral combinations
Other antivirals for hepatitis C
Antiprotozoal medicines
Antiamoebic and antigiardiasis medicines
Antileishmaniasis medicines
Antimalarial medicines
Medicines for curative treatment
Medicines for chemoprevention
Medicines for chemoprophylaxis in travellers
Antipneumocystosis and antitoxoplasmosis medicines
Complementary:
Antitrypanosomal medicines
African trypanosomiasis
Medicines for the treatment of 1st stage African trypanosomiasis
Medicines for the treatment of 2nd stage African trypanosomiasis
Complementary:
American trypanosomiasis
Medicines for ectoparasitic infections
Medicines for Ebola virus disease
Medicines for COVID-19
No listings in this section.
Medicines for cystic fibrosis
Complementary:
Immunomodulators and antineoplastics
Immunomodulators for non-malignant disease
Complementary:
Antineoplastics and supportive medicines
Cytotoxic medicines
Complementary:
Targeted therapies
Complementary:
Immunomodulators
Complementary:
Hormones and antihormones
Complementary:
Supportive medicines
Complementary:
Therapeutic foods
Medicines affecting the blood
Antianaemia medicines
Complementary:
Medicines affecting coagulation
Complementary:
Medicines for haemoglobinopathies
Medicines for sickle-cell disease
Complementary:
Medicines for thalassaemias
Complementary:
Blood products, coagulation factors and plasma substitutes
Blood and blood components
Human immunoglobulins
Complementary:
Coagulation factors
Plasma substitutes
Cardiovascular medicines
Antianginal medicines
Antiarrhythmic medicines
Complementary:
Antihypertensive medicines
Complementary:
Medicines used in heart failure
Complementary:
Antithrombotic medicines
Anti-platelet medicines
Thrombolytic medicines
Complementary:
Lipid-lowering agents
Fixed-dose combinations of various agents for prevention of atherosclerotic cardiovascular disease (also referred to as "polypills")
The first patent, Liang MH, Manson JE. (US Patent No. 6,576,256) [âÂÂPolypillâÂÂ]. Treatment of patients at Elevated Cardiovascular Risk with a Combination of a Cholesterol Lowering Agent, an Inhibitor of the Renin-Angiotensin System, and Aspirin, submitted 2001; awarded and assigned to Brigham and WomenâÂÂs Hospital, 2003.
Dermatological medicines
Antifungal medicines
Anti-infective medicines
Anti-inflammatory and antipruritic medicines
Medicines affecting skin differentiation and proliferation
Complementary:
Scabicides and pediculicides
Moisturizers
Sunscreens, broad-spectrum
Diagnostic agents
Ophthalmic medicines
Radiocontrast media
Complementary:
Antiseptics and disinfectants
Antiseptics
Disinfectants
Diuretics
Complementary:
Gastrointestinal medicines
Complementary:
Antiulcer medicines
Antiemetic medicines
Complementary:
Anti-inflammatory medicines
Complementary:
Laxatives
Medicines used in diarrhea
Oral rehydration
Medicines for diarrhoea
Medicines for endocrine disorders
Adrenal hormones and synthetic substitutes
Androgens
Complementary:
Estrogens
No listings in this section.
Progestogens
Medicines for diabetes
Insulins
Hypoglycaemic agents
Complementary:
Medicines for hypoglycaemia
Complementary:
Thyroid hormones and antithyroid medicines
Complementary:
Medicines for disorders of the pituitary hormone system
Complementary:
Immunologicals
Diagnostic agents
Sera, immunoglobulins and monoclonal antibodies
Vaccines
Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
Complementary:
Ophthalmological preparations
Anti-infective agents
Anti-inflammatory agents
Local anaesthetics
Miotics and antiglaucoma medicines
Mydriatics
Complementary:
Anti-vascular endothelial growth factor (VEGF) preparations
Complementary:
Medicines for reproductive health and perinatal care
Contraceptives
Oral hormonal contraceptives
Injectable hormonal contraceptives
Intrauterine devices
Barrier methods
Implantable contraceptives
Intravaginal contraceptives
Ovulation inducers
Complementary:
Uterotonics
Medicines for medical abortion
Antioxytocics (tocolytics)
Other medicines administered to the mother
Medicines administered to the neonate
Complementary:
Peritoneal dialysis solution
Complementary:
Medicines for mental and behavioural disorders
Medicines used in psychotic disorders
Complementary:
Medicines used in mood disorders
Medicines used in depressive disorders
Medicines used in bipolar disorders
Medicines for anxiety disorders
Medicines used for obsessive compulsive disorders
Medicines for disorders due to psychoactive substance use
Medicines for alcohol use disorders
Medicines for nicotine use disorders
Medicines for opioid use disorders
Complementary:
Medicines acting on the respiratory tract
Antiasthmatic medicines and medicines for chronic obstructive pulmonary disease
Solutions correcting water, electrolyte and acid-base disturbances
Oral
Parenteral
Miscellaneous
Vitamins and minerals
Complementary:
Ear, nose and throat medicines
Medicines for diseases of joints
Medicines used to treat gout
Disease-modifying anti-rheumatic drugs (DMARDs)
Complementary:
Medicines for juvenile joint diseases
Complementary:
Dental medicines and preparations
Notes
An ñ indicates the medicine is on the complementary list for which specialized diagnostic or monitoring or training is needed. An item may also be listed as complementary on the basis of higher costs or a less attractive cost-benefit ratio.
References
Further reading
External links